Welcome!
RHB Securities
Broker's Calls
Hyphens Pharma weathers Covid-19 storm with increases in all segments
“COVID-19 has created a challenging operating environment, however, we remain agile and to adapt to a different operating environment,” says Hyphens Pharma’s executive chairman & CEO Lim See Wah
May 15, 2020
Broker's Calls
RHB remains 'neutral' towards Centurion despite its Covid-19 bug
Collectively, the hit from the pandemic on the group’s PBSA and PBWA properties has made Lee and Cai shaving their FY20F-22F earnings by 25% (FY20), 15% (FY21), and 4% (FY22) respectively.
April 29, 2020
Investing ideas
RHB's choice of stocks with earnings and dividends growth prospects for anxious times
Fu Yu, Oxley and Avi-Tech are a few gems that investors can consider, says Jarick Seet, Head of small and mid caps at RHB.
February 28, 2020